United States Benign Prostatic Hyperplasia (BPH) Drugs Market Report 2017

Name: United States Benign Prostatic Hyperplasia (BPH) Drugs Market Report 2017
Brand: QYResearch
SKU: U9E92235982PEN
Price: 3800 USD
Availability: InStock

October 2017 | 109 pages | ID: U9E92235982PEN
QYResearch

US$ 3,800.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer

Checkout Later

Need Help? Ask a Question

In this report, the United States Benign Prostatic Hyperplasia (BPH) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

The West
Southwest
The Middle Atlantic
New England
The South
The Midwest
with sales (volume), revenue (value), market share and growth rate of Benign Prostatic Hyperplasia (BPH) Drugs in these regions, from 2012 to 2022 (forecast).

United States Benign Prostatic Hyperplasia (BPH) Drugs market competition by top manufacturers/players, with Benign Prostatic Hyperplasia (BPH) Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
ADC Therapeutics
Advaxis
Agennix
ANI Pharmaceuticals
BHR Pharma
Bristol-Myers Squibb
Boehringer Ingelheim
Dendreo
Endo Pharmaceuticals

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

Alpha-blocker
Phosphodiesterase type-5 inhibitors
5-alpha-Reductase inhibitors

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Benign Prostatic Hyperplasia (BPH) Drugs for each application, including

Clinical medicine
Scientific research
Others

United States Benign Prostatic Hyperplasia (BPH) Drugs Market Report 2017

1 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS OVERVIEW

1.1 Product Overview and Scope of Benign Prostatic Hyperplasia (BPH) Drugs
1.2 Classification of Benign Prostatic Hyperplasia (BPH) Drugs by Product Category
  1.2.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Alpha-blocker
  1.2.4 Phosphodiesterase type-5 inhibitors
  1.2.5 5-alpha-Reductase inhibitors
1.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Market by Application/End Users
  1.3.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Clinical medicine
  1.3.3 Scientific research
  1.3.4 Others
1.4 United States Benign Prostatic Hyperplasia (BPH) Drugs Market by Region
  1.4.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Benign Prostatic Hyperplasia (BPH) Drugs Status and Prospect (2012-2022)
  1.4.3 Southwest Benign Prostatic Hyperplasia (BPH) Drugs Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Benign Prostatic Hyperplasia (BPH) Drugs Status and Prospect (2012-2022)
  1.4.5 New England Benign Prostatic Hyperplasia (BPH) Drugs Status and Prospect (2012-2022)
  1.4.6 The South Benign Prostatic Hyperplasia (BPH) Drugs Status and Prospect (2012-2022)
  1.4.7 The Midwest Benign Prostatic Hyperplasia (BPH) Drugs Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Benign Prostatic Hyperplasia (BPH) Drugs (2012-2022)
  1.5.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2022)
  1.5.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2012-2022)

2 UNITED STATES BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Players/Suppliers (2012-2017)
2.4 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Competitive Situation and Trends
  2.4.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Concentration Rate
  2.4.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Region (2012-2017)
3.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Region (2012-2017)
3.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Price by Region (2012-2017)

4 UNITED STATES BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Type (2012-2017)
4.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2012-2017)
4.4 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate by Type (2012-2017)

5 UNITED STATES BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Application (2012-2017)
5.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Astellas Pharma
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Eli Lilly
  6.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 GlaxoSmithKline
  6.3.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Sanofi
  6.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 ADC Therapeutics
  6.5.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Advaxis
  6.6.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Agennix
  6.7.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Agennix Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 ANI Pharmaceuticals
  6.8.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 BHR Pharma
  6.9.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Bristol-Myers Squibb
  6.10.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Boehringer Ingelheim
6.12 Dendreo
6.13 Endo Pharmaceuticals

7 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MANUFACTURING COST ANALYSIS

7.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Benign Prostatic Hyperplasia (BPH) Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Forecast by Type (2017-2022)
11.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Forecast by Application (2017-2022)
11.4 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

LIST OF TABLES AND FIGURES

Figure Product Picture of Benign Prostatic Hyperplasia (BPH) Drugs
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Market Size (MT) by Type (2012-2022)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Alpha-blocker Product Picture
Figure Phosphodiesterase type-5 inhibitors Product Picture
Figure 5-alpha-Reductase inhibitors Product Picture
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Market Size (MT) by Application (2012-2022)
Figure United States Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application in 2016
Figure Clinical medicine Examples
Figure Scientific research Examples
Figure Others Examples
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Market Size (Million USD) by Region (2012-2022)
Figure The West Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2022)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Market Major Players Product Sales Volume (MT) (2012-2017)
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) of Key Players/Suppliers (2012-2017)
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Players/Suppliers
Figure 2017 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Players/Suppliers
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Players/Suppliers
Figure 2017 United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Players/Suppliers
Table United States Market Benign Prostatic Hyperplasia (BPH) Drugs Average Price (USD/Kg) of Key Players/Suppliers (2012-2017)
Figure United States Market Benign Prostatic Hyperplasia (BPH) Drugs Average Price (USD/Kg) of Key Players/Suppliers in 2016
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Market Share of Top 3 Players/Suppliers
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Benign Prostatic Hyperplasia (BPH) Drugs Product Category
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) by Region (2012-2017)
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Region (2012-2017)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Region (2012-2017)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region in 2016
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Region (2012-2017)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2012-2017)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region in 2016
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Price (USD/Kg) by Region (2012-2017)
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) by Type (2012-2017)
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2012-2017)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2012-2017)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2016
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2012-2017)
Figure Revenue Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type in 2016
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Price (USD/Kg) by Types (2012-2017)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate by Type (2012-2017)
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) by Application (2012-2017)
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2012-2017)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2012-2017)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2016
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate by Application (2012-2017)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate by Application (2012-2017)
Table Astellas Pharma Basic Information List
Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2012-2017)
Figure Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in United States (2012-2017)
Figure Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in United States (2012-2017)
Table Eli Lilly Basic Information List
Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2012-2017)
Figure Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in United States (2012-2017)
Figure Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in United States (2012-2017)
Table GlaxoSmithKline Basic Information List
Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2012-2017)
Figure GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in United States (2012-2017)
Figure GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in United States (2012-2017)
Table Sanofi Basic Information List
Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2012-2017)
Figure Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in United States (2012-2017)
Figure Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in United States (2012-2017)
Table ADC Therapeutics Basic Information List
Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2012-2017)
Figure ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in United States (2012-2017)
Figure ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in United States (2012-2017)
Table Advaxis Basic Information List
Table Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2012-2017)
Figure Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in United States (2012-2017)
Figure Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in United States (2012-2017)
Table Agennix Basic Information List
Table Agennix Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Agennix Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2012-2017)
Figure Agennix Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in United States (2012-2017)
Figure Agennix Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in United States (2012-2017)
Table ANI Pharmaceuticals Basic Information List
Table ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2012-2017)
Figure ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in United States (2012-2017)
Figure ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in United States (2012-2017)
Table BHR Pharma Basic Information List
Table BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2012-2017)
Figure BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in United States (2012-2017)
Figure BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in United States (2012-2017)
Table Bristol-Myers Squibb Basic Information List
Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2012-2017)
Figure Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in United States (2012-2017)
Figure Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in United States (2012-2017)
Table Boehringer Ingelheim Basic Information List
Table Dendreo Basic Information List
Table Endo Pharmaceuticals Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Benign Prostatic Hyperplasia (BPH) Drugs
Figure Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
Figure Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis
Table Raw Materials Sources of Benign Prostatic Hyperplasia (BPH) Drugs Major Players/Suppliers in 2016
Table Major Buyers of Benign Prostatic Hyperplasia (BPH) Drugs
Table Distributors/Traders List
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT) and Growth Rate Forecast (2017-2022)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Price (USD/Kg) Trend Forecast (2017-2022)
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT) Forecast by Type (2017-2022)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT) Forecast by Type (2017-2022)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT) Forecast by Type in 2022
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT) Forecast by Application (2017-2022)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT) Forecast by Application (2017-2022)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT) Forecast by Application in 2022
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT) Forecast by Region (2017-2022)
Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

United States Benign Prostatic Hyperplasia (BPH) Drugs Market Report 2017

More Publications

Need Help?

Ask a Question

Market Reports